Gudmundsdottir Hallbera, Möller Páll Helgi, Jonasson Jon Gunnlaugur, Björnsson Einar S
a Department of Internal Medicine, Division of Gastroenterology , Landspitali University Hospital , Reykjavik , Iceland.
b Department of Surgery, Division of Abdominal Surgery , Landspitali University Hospital , Reykjavik , Iceland.
Scand J Gastroenterol. 2019 Jan;54(1):69-75. doi: 10.1080/00365521.2018.1553061. Epub 2019 Jan 13.
To determine the incidence, distribution, and prognosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) over the last 30 years and analyze changes over time.
All patients diagnosed with GEP-NETs in Iceland from 1985 to 2014 were identified through the Icelandic Cancer Registry and pathology laboratory records. Relevant clinical information was obtained from medical records. In order to assess trends, the study period was divided into two periods, 1985-1999 and 2000-2014.
A total of 364 patients with GEP-NETs were identified. Overall, 18 patients diagnosed at autopsy or with primary tumors of an unknown site were excluded, leaving 346 patients with 351 primary tumors for final analysis. The overall mean annual incidence 1985-2014 was 3.65/100,000, 3.39/100,000 during 1985-1999 and 3.85/100,000 during 2000-2014 (p = NS). The most common primary tumor site was the appendix (32%), followed by the jejunum/ileum (24%) and stomach (17%). In all, 18% of patients presented with distant metastases at the time of diagnosis, most noticeably patients with primary tumors of the colon (47%), pancreas (46%) and jejunum/ileum (39%). The most favorable 5-year survival was observed for tumors of the appendix (94%) and rectum (88%) and the least favorable for tumors of the pancreas (31%), colon (47%) and jejunum/ileum (66%). There were no statistically significant changes in incidence, staging or survival between the two time periods.
In this population-based study, the incidence of GEP-NETs has not changed significantly over the last decades. The incidence of metastatic disease has remained stable and overall prognosis has not improved in recent years.
确定过去30年胃肠胰神经内分泌肿瘤（GEP-NETs）的发病率、分布及预后情况，并分析其随时间的变化。
通过冰岛癌症登记处和病理实验室记录，确定1985年至2014年在冰岛被诊断为GEP-NETs的所有患者。从医疗记录中获取相关临床信息。为评估趋势，研究期分为两个阶段，即1985 - 1999年和2000 - 2014年。
共识别出364例GEP-NETs患者。总体而言，18例经尸检诊断或原发肿瘤部位不明的患者被排除，最终分析留下346例患者的351个原发肿瘤。1985 - 2014年总体年均发病率为3.65/10万，1985 - 1999年为3.39/10万，2000 - 2014年为3.85/10万（p =无统计学意义）。最常见的原发肿瘤部位是阑尾（32%），其次是空肠/回肠（24%）和胃（17%）。总体而言，18%的患者在诊断时出现远处转移，最显著的是结肠（47%）、胰腺（46%）和空肠/回肠（39%）原发肿瘤患者。阑尾（94%）和直肠（88%）肿瘤的5年生存率最有利，而胰腺（31%）、结肠（47%）和空肠/回肠（66%）肿瘤的5年生存率最不利。两个时间段之间在发病率、分期或生存率方面无统计学显著变化。
在这项基于人群的研究中，过去几十年GEP-NETs的发病率没有显著变化。转移性疾病的发病率保持稳定，近年来总体预后没有改善。
